FNBT
ATRA icon

FineMark National Bank & Trust’s Atara Biotherapeutics ATRA Stock Holding History

FineMark National Bank & Trust’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1
Closed -$1K – 1351
2015
Q3 		$1K Buy
+1
New +$1.22K ﹤0.01% 1347

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FineMark National Bank & Trust's ATRA Position: Q4 2015 in Review

FineMark National Bank & Trust sold out of Atara Biotherapeutics (ATRA) in Q4 2015, closing a stake of 1 share — an estimated $1K sold.

FineMark National Bank & Trust first reported a position in ATRA in Q3 2015 and held it in 1 quarter. The position peaked at $1K in Q3 2015. 84 funds tracked by Wall St. Rank hold ATRA as of Q4 2015.

  • FineMark National Bank & Trust reported no remaining Atara Biotherapeutics position as of Q4 2015 after selling out during the quarter.
  • FineMark National Bank & Trust sold 1 Atara Biotherapeutics share in Q4 2015, an estimated $1K.
  • FineMark National Bank & Trust first reported a position in Atara Biotherapeutics in Q3 2015 and held it in 1 quarter.
  • FineMark National Bank & Trust's Atara Biotherapeutics position peaked at $1K in Q3 2015.
  • 84 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2015.

Based on FineMark National Bank & Trust's 13F filing for Q4 2015, filed 9 Feb 2016.